Abstract:Background In LUX-Lung 8 (LL8), second-line afatinib (A) significantly improved PFS and OS vs erlotinib (E) in patients (pts) with squamous cell carcinoma of the lung (N=795).We report exploratory molecular analyses (n=245) and immunohistochemistry (IHC; n=288) of LL8 tumor samples to assess frequency of short variants (SVs) and copy number alterations (CNAs) in cancer-related genes, and clinical utility of genomic alterations or EGFR expression levels as predictive biomarkers. We also assessed the predictive utility of the prospectively validated VeriStratVR (VS) test, a serum protein test (n=675). Methods Tumor samples were analyzed by FoundationOneTM next-generation sequencing. EGFR positivity (by IHC) was defined as staining in > 10% of cells (Method 1) or H-score >200 (Method 2). Pretreatment serum samples were assigned as VS- Good (VS-G) or VS-Poor (VS-P) by mass spectrometry signature. Cox regression analysis was used to correlate PFS/OS with genomic alterations (individual or grouped, e.g. ErbB family), EGFR expression, and VS status. Results The frequency of ErbB family alterations was low (SVs: EGFR 6.5%, HER2 4.9%, HER3 6.1%, HER4 5.7%; CNAs: EGFR 6.9%, HER2 3.7%). No individual genetic or ErbB family alterations were predictive of PFS/OS. Treatment (tx) benefit from A vs E was consistent in all molecular subgroups. EGFR expression was not predictive of PFS/OS benefit (Table). PFS and OS were improved (p < 0.0001) in the VS-G vs VS-P group (Table). VS-G pts had significantly longer PFS (median 3.3 vs 2.0 mos) and OS (median 11.5 vs 8.9 mos) with A vs E, while VS-P pts had no significant difference in PFS/OS with A vs E (Table). There was no significant interaction between tx arms and VS classification. Conclusions No biomarkers were identified that predicted benefit with A over E in LL8 pts. A is a tx option in this setting irrespective of tumor characteristics. However, pt outcome strongly depends on VS status. Conclusions No biomarkers were identified that predicted benefit with A over E in LL8 pts. A is a tx option in this setting irrespective oftumor characteristics. However, pt outcome strongly depends on VS status. Table: 446PDTabled 1Table: 446PDPFS and OS in patients assessed by IHC and VeriStratPFSOSHR95% CIHR95% CIIHC Method 1EGFR + (A: 82%; E: 86%)0.760.57-1.020.840.63-1.12EGFR- (A: 18%; E: 14%)0.870.45-1.680.770.40-1.51IHC Method 2EGFR+ (A: 28%; E: 37%)0.780.47-1.300.690.42-1.13EGFR- (A: 72%; E: 63%)0.760.55-1.050.690.42-1.13VeriStratVS-G vs VS-P0.650.54-0.770.410.35-0.49A vs E (VS-G group)0.730.59-0.920.790.63-0.98A vs E (VS-P group)0.970.73-1.270.90.70-1.16 Open table in a new tab Clinical trial indentification NCT01523587 Legal entity responsible for the study N/A Funding: Boehringer Ingelheim Disclosure J-C. Soria: Honoraria: BI, Roche. E. Felip: Honoraria: Boeheringer Ingelheim, MSD, Eli Lilly, Roche, Pfizer, Novartis, BMS, Celgene Consultancy/Advisory board: Boeheringer Ingelheim, MSD, Eli Lilly, Roche, Pfizer, Novartis, BMS, Celgene Speakers bureau: BMS, Novartis, Roche. A. Ardizzoni: Advisory board: BI Honoraria: BMS, MSD. S.M. Gadgeel: Advisory board: Boehringer-Ingelheim, Genentech/Roche, Astra-Zeneca. N. Dupuis: Employment Biodesix, Inc. Stock ownership or options Biodesix, Inc. N.J. Gibson, N. Kr€amer: Employment: Boehringer Ingelheim Pharma GmbH & Co. KG. C. Bu¨hnemann: Employment: BI. F. Solca: Employment: Boehringer Ingelheim RCV GmbH & Co KG. E. Ehrnrooth: Employment: Boehringer Ingelheim. G. Goss: Advisory board: AstraZeneca, Boehringer Ingelheim, BMS, Pfizer Honoraria: AstraZeneca, Boehringer Ingelheim, BMS, Pfizer. All other authors have declared no conflicts of interest.

A Retrospective Analysis Of The Icogen Clinical Trial Demonstrates The Utility Of Veristrat To Predict Outcome In An All Chinese Cohort Treated With Egfr Tki.

Safety and Efficacy Results of A Phase Iv, Open-Label, Multicenter, Safety-Monitoring Study of Icotinib in Treating Advanced Non-Small Cell Lung Cancer (nsclc): Isafe Study.

An Updated Analysis of ICOGEN to Demonstrate Utility of a Blood-Based Proteomic Test to Predict Outcomes in EGFR TKI Treated Patients.

A Single-Arm, Multicenter, Safety-Monitoring, Phase IV Study of Icotinib in Treating Advanced Non-Small Cell Lung Cancer (NSCLC).

Evaluation of the VeriStrat® Serum Protein Test in Patients with Advanced Squamous Cell Carcinoma of the Lung Treated with Second-Line Afatinib or Erlotinib in the Phase III LUX-Lung 8 Study

Icotinib Versus Vinorelbine/platinum As Adjuvant Therapy in Stage II-IIIA Non-Small Cell Lung Cancer with EGFR-mutations: A Multicenter, Randomized, Positive-Controlled, Phase 3, Indication-Expanding Study (EVIDENCE, CCTC-1501).

Icotinib Versus Chemotherapy As Adjuvant Treatment for Stage II–IIIA EGFR-mutant Non-Small-cell Lung Cancer (EVIDENCE): a Randomised, Open-Label, Phase 3 Trial

Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis

Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing A Phase 2 Nonrandomized Clinical Trial

Abstract 7099: Prognostic value of serum proteomic signature in NSCLC patients on immune checkpoint inhibitors: Impact of treatment regimen and PD-L1 levels

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).

P3.02b-003 Second-Line Afatinib Versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (Lux-Lung 8): Analysis of Tumor and Serum Biomarkers: Topic: EGFR Biomarkers

446PD Second-line Afatinib Vs Erlotinib for Patients with Squamous Cell Carcinoma of the Lung in LUX-Lung 8: Analysis of Tumor and Serum Biomarkers

Genomic Signature for Personalized Adjuvant Therapy in Resected EGFR-Mutant Stage II-III Non-Small Cell Lung Cancer: Results from Phase 3 ADJVANT/CTONG1104 Study

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study

Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study

The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial

Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China

Efficiency Of Anlotinib Hydrochloride As 3rd Line Treatment In Patients (Pts) From A Randomized, Double-Blind, Placebo-Controlled Phase Iii Trial, An Exploratory Subgroup Analysis Of Alter0303 Trial For The Previous Therapy Strategy Effect